JP2020520356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520356A5 JP2020520356A5 JP2019563491A JP2019563491A JP2020520356A5 JP 2020520356 A5 JP2020520356 A5 JP 2020520356A5 JP 2019563491 A JP2019563491 A JP 2019563491A JP 2019563491 A JP2019563491 A JP 2019563491A JP 2020520356 A5 JP2020520356 A5 JP 2020520356A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- pyrimidine
- ethylamino
- ethoxy
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxy Chemical group 0.000 claims 134
- 125000000217 alkyl group Chemical group 0.000 claims 99
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 239000001257 hydrogen Substances 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000004430 oxygen atom Chemical group O* 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000002947 alkylene group Chemical group 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 5
- 125000002993 cycloalkylene group Chemical group 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- CTQPPUPWHLGKOB-UHFFFAOYSA-N 4h-oxadiazol-5-one Chemical compound O=C1CN=NO1 CTQPPUPWHLGKOB-UHFFFAOYSA-N 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 210000000987 immune system Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 238000002626 targeted therapy Methods 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- QJGLOGMNORETMH-UHFFFAOYSA-N 3-[3-ethoxy-5-[6-[2-(2,4,6-trifluorophenyl)ethylamino]pyrimidin-4-yl]thiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1F)F)F)C1=NOC(N1)=O QJGLOGMNORETMH-UHFFFAOYSA-N 0.000 claims 2
- QBXRJYJOLLINKR-UHFFFAOYSA-N 3-[3-ethoxy-5-[6-[2-(2-ethoxy-4-fluorophenyl)ethylamino]pyrimidin-4-yl]thiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)F)OCC)C1=NOC(N1)=O QBXRJYJOLLINKR-UHFFFAOYSA-N 0.000 claims 2
- XLDCYMRZFRLVNW-UHFFFAOYSA-N 3-[3-ethoxy-5-[6-[2-(2-ethyl-4-methoxyphenyl)ethylamino]pyrimidin-4-yl]thiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)OC)CC)C1=NOC(N1)=O XLDCYMRZFRLVNW-UHFFFAOYSA-N 0.000 claims 2
- BWAJWJWTQHXEEH-UHFFFAOYSA-N 3-[3-ethoxy-5-[6-[2-(2-fluoro-4-methoxyphenyl)ethylamino]pyrimidin-4-yl]thiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)OC)F)C1=NOC(N1)=O BWAJWJWTQHXEEH-UHFFFAOYSA-N 0.000 claims 2
- ZXFCHOFSTUKCOJ-UHFFFAOYSA-N 3-[3-ethoxy-5-[6-[2-[2-ethoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]thiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)C(F)(F)F)OCC)C1=NOC(N1)=O ZXFCHOFSTUKCOJ-UHFFFAOYSA-N 0.000 claims 2
- VQJPXXKFYYMECV-UHFFFAOYSA-N 3-[3-ethoxy-5-[6-[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]thiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)C(F)(F)F)F)C1=NOC(N1)=O VQJPXXKFYYMECV-UHFFFAOYSA-N 0.000 claims 2
- ZONNJMNMMNSKOJ-UHFFFAOYSA-N 3-[5-[6-[2-(2,4-dichlorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound ClC1=C(C=CC(=C1)Cl)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC ZONNJMNMMNSKOJ-UHFFFAOYSA-N 0.000 claims 2
- GNYYWFUXPSBBRU-UHFFFAOYSA-N 3-[5-[6-[2-(3,4-dichlorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound ClC=1C=C(C=CC=1Cl)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC GNYYWFUXPSBBRU-UHFFFAOYSA-N 0.000 claims 2
- BJCIBKZOVPPABF-UHFFFAOYSA-N 3-[5-[6-[2-(4-bromo-2-chlorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound BrC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC)Cl BJCIBKZOVPPABF-UHFFFAOYSA-N 0.000 claims 2
- CCDDZTDNMKMWIV-UHFFFAOYSA-N 3-[5-[6-[2-(4-bromo-2-ethoxyphenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound BrC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC)OCC CCDDZTDNMKMWIV-UHFFFAOYSA-N 0.000 claims 2
- CYIGQRURNVPKFK-UHFFFAOYSA-N 3-[5-[6-[2-(4-bromo-3-chlorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]-4H-1,2,4-oxadiazol-5-one Chemical compound BrC1=C(C=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC)Cl CYIGQRURNVPKFK-UHFFFAOYSA-N 0.000 claims 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 2
- KPCBRVFEMIFEJW-UHFFFAOYSA-N 5-[4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-methoxyphenyl]-1,2-oxazol-3-one Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C=C1)C1=CC(=NO1)O)OC)F KPCBRVFEMIFEJW-UHFFFAOYSA-N 0.000 claims 2
- ZCHNCEWRBASKAC-UHFFFAOYSA-N 5-[5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]-3H-1,3,4-oxadiazol-2-one Chemical compound CCOc1cc(sc1-c1n[nH]c(=O)o1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 ZCHNCEWRBASKAC-UHFFFAOYSA-N 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 2
- BQCLVOBRRWQCTM-UHFFFAOYSA-N BrC1=C(C=C(C=C1)Cl)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC Chemical compound BrC1=C(C=C(C=C1)Cl)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC BQCLVOBRRWQCTM-UHFFFAOYSA-N 0.000 claims 2
- ABTIJEQHHVCFBA-UHFFFAOYSA-N BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC(=N1)C)C1=CC(=C(S1)C1=NOC(N1)=O)OCC)F Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC(=N1)C)C1=CC(=C(S1)C1=NOC(N1)=O)OCC)F ABTIJEQHHVCFBA-UHFFFAOYSA-N 0.000 claims 2
- FOFKQTVWIRYJIL-UHFFFAOYSA-N BrC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC)F Chemical compound BrC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(N1)=O)OCC)F FOFKQTVWIRYJIL-UHFFFAOYSA-N 0.000 claims 2
- HNSLOVZJVRHJNB-UHFFFAOYSA-N C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC(=C(C=C1)O)OC)C1=NOC(N1)=O Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC(=C(C=C1)O)OC)C1=NOC(N1)=O HNSLOVZJVRHJNB-UHFFFAOYSA-N 0.000 claims 2
- DMRVMUKPEWYJIE-UHFFFAOYSA-N C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC(=C(C=C1)OC)O)C1=NOC(N1)=O Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC(=C(C=C1)OC)O)C1=NOC(N1)=O DMRVMUKPEWYJIE-UHFFFAOYSA-N 0.000 claims 2
- GOBGCXSMLFKIOV-UHFFFAOYSA-N C(C)OC=1C=C(SC=1C1=NOC(N1)=O)C1=CC(=NC=N1)NCCC1=C(C#N)C=C(C=C1)F Chemical compound C(C)OC=1C=C(SC=1C1=NOC(N1)=O)C1=CC(=NC=N1)NCCC1=C(C#N)C=C(C=C1)F GOBGCXSMLFKIOV-UHFFFAOYSA-N 0.000 claims 2
- JPZFVNWNJMAJJZ-UHFFFAOYSA-N CC(C)Oc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 Chemical compound CC(C)Oc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 JPZFVNWNJMAJJZ-UHFFFAOYSA-N 0.000 claims 2
- CFHTYTITSCAMJO-UHFFFAOYSA-N CCCOc1cc(Br)ccc1CCNc1cc(ncn1)-c1cc(OCC)c(s1)-c1nc(=O)o[nH]1 Chemical compound CCCOc1cc(Br)ccc1CCNc1cc(ncn1)-c1cc(OCC)c(s1)-c1nc(=O)o[nH]1 CFHTYTITSCAMJO-UHFFFAOYSA-N 0.000 claims 2
- YZBLXDGRXJUMST-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 YZBLXDGRXJUMST-UHFFFAOYSA-N 0.000 claims 2
- ZUCGPYSNZVAQIC-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2OC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2OC)ncn1 ZUCGPYSNZVAQIC-UHFFFAOYSA-N 0.000 claims 2
- WUPMIHQBWMCPMJ-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Cl)cc2F)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Cl)cc2F)ncn1 WUPMIHQBWMCPMJ-UHFFFAOYSA-N 0.000 claims 2
- TXDYFXUYEGNEOD-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Cl)cc2OC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Cl)cc2OC)ncn1 TXDYFXUYEGNEOD-UHFFFAOYSA-N 0.000 claims 2
- RVIRCDAIZVACJY-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)ccc(Cl)c2F)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)ccc(Cl)c2F)ncn1 RVIRCDAIZVACJY-UHFFFAOYSA-N 0.000 claims 2
- SCNUSBVKWLHESZ-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)ccc(F)c2Cl)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)ccc(F)c2Cl)ncn1 SCNUSBVKWLHESZ-UHFFFAOYSA-N 0.000 claims 2
- OPQZQPVWLKFNEX-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(OC)cc(Br)cc2OC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(OC)cc(Br)cc2OC)ncn1 OPQZQPVWLKFNEX-UHFFFAOYSA-N 0.000 claims 2
- KXHVBNVHUDENBB-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(Br)ccc2OC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(Br)ccc2OC)ncn1 KXHVBNVHUDENBB-UHFFFAOYSA-N 0.000 claims 2
- CPOOEZIRKAQMNY-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(Br)ccc2SC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(Br)ccc2SC)ncn1 CPOOEZIRKAQMNY-UHFFFAOYSA-N 0.000 claims 2
- PQTCZKGSFJBZDE-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(C)c(Br)cc2F)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(C)c(Br)cc2F)ncn1 PQTCZKGSFJBZDE-UHFFFAOYSA-N 0.000 claims 2
- SFPPOLYJLCGTTH-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(F)c(Br)cc2C)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(F)c(Br)cc2C)ncn1 SFPPOLYJLCGTTH-UHFFFAOYSA-N 0.000 claims 2
- CKSMZXUBYYRCDE-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(F)c(Br)cc2F)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cc(F)c(Br)cc2F)ncn1 CKSMZXUBYYRCDE-UHFFFAOYSA-N 0.000 claims 2
- GMGVAJQAPSHSQY-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)c(C)c2)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)c(C)c2)ncn1 GMGVAJQAPSHSQY-UHFFFAOYSA-N 0.000 claims 2
- OIFKKSNOGUYHTN-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)c(F)c2)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)c(F)c2)ncn1 OIFKKSNOGUYHTN-UHFFFAOYSA-N 0.000 claims 2
- NZHLLPGMJXMIMG-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)c(OC)c2)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)c(OC)c2)ncn1 NZHLLPGMJXMIMG-UHFFFAOYSA-N 0.000 claims 2
- TYPROPXGGIXTSL-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)cc2)nc(C)n1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)cc2)nc(C)n1 TYPROPXGGIXTSL-UHFFFAOYSA-N 0.000 claims 2
- KJGXATJADPBWQG-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)cc2C)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)cc2C)ncn1 KJGXATJADPBWQG-UHFFFAOYSA-N 0.000 claims 2
- AQXNCPATZYQJGJ-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)cc2OC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(Br)cc2OC)ncn1 AQXNCPATZYQJGJ-UHFFFAOYSA-N 0.000 claims 2
- RJMNOJSFWLQMDK-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(C)c(C)c2)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(C)c(C)c2)ncn1 RJMNOJSFWLQMDK-UHFFFAOYSA-N 0.000 claims 2
- LSIWUEBJGBSNQC-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(OC)c(Cl)c2)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(OC)c(Cl)c2)ncn1 LSIWUEBJGBSNQC-UHFFFAOYSA-N 0.000 claims 2
- WWBYVLRDLXFHLU-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(OC)cc2OC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(OC)cc2OC)ncn1 WWBYVLRDLXFHLU-UHFFFAOYSA-N 0.000 claims 2
- HBLHCAZBELMRGY-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(cc2F)N(C)C)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2ccc(cc2F)N(C)C)ncn1 HBLHCAZBELMRGY-UHFFFAOYSA-N 0.000 claims 2
- ZLEWETBNRXECTR-UHFFFAOYSA-N CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cccc(OC)c2OC)ncn1 Chemical compound CCOc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2cccc(OC)c2OC)ncn1 ZLEWETBNRXECTR-UHFFFAOYSA-N 0.000 claims 2
- MCYZOGQNPSVEGA-UHFFFAOYSA-N CCOc1nc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 Chemical compound CCOc1nc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 MCYZOGQNPSVEGA-UHFFFAOYSA-N 0.000 claims 2
- WZCGEZVZOGHCNO-UHFFFAOYSA-N CCc1nc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 Chemical compound CCc1nc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 WZCGEZVZOGHCNO-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- SCEQAWUNWZOOLR-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(=N1)O)OCC Chemical compound FC1=C(C(=CC=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C1=NOC(=N1)O)OCC SCEQAWUNWZOOLR-UHFFFAOYSA-N 0.000 claims 2
- BSZWDEJEHIKFIJ-UHFFFAOYSA-N Fc1cc(Br)cc(F)c1CCNc1cc(ncn1)-c1cc(c(s1)-c1nc(=O)o[nH]1)C(F)(F)F Chemical compound Fc1cc(Br)cc(F)c1CCNc1cc(ncn1)-c1cc(c(s1)-c1nc(=O)o[nH]1)C(F)(F)F BSZWDEJEHIKFIJ-UHFFFAOYSA-N 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- BOWYQHCFTNADQJ-UHFFFAOYSA-N OC1=CN=NO1 Chemical compound OC1=CN=NO1 BOWYQHCFTNADQJ-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000035558 fertility Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000007420 reactivation Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- LIZZTEYNQCHKKS-ONEGZZNKSA-N (E)-3-[5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]prop-2-enoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)/C=C/C(=O)O)OCC)F LIZZTEYNQCHKKS-ONEGZZNKSA-N 0.000 claims 1
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical compound OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 claims 1
- UPOSDIJZIPMWJK-UHFFFAOYSA-N 2-[2-ethoxy-4-[6-[2-[2-ethoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]phenyl]acetic acid Chemical compound C(C)OC1=C(C=CC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)C(F)(F)F)OCC)CC(=O)O UPOSDIJZIPMWJK-UHFFFAOYSA-N 0.000 claims 1
- UNYZZEYKJJLGQR-UHFFFAOYSA-N 2-[4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-chloro-6-ethylphenyl]acetic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=C1)CC)CC(=O)O)Cl)F UNYZZEYKJJLGQR-UHFFFAOYSA-N 0.000 claims 1
- DFFMMMFVYYAYQJ-UHFFFAOYSA-N 2-[4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethoxyanilino]-2-oxoacetic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C=C1)NC(C(=O)O)=O)OCC)F DFFMMMFVYYAYQJ-UHFFFAOYSA-N 0.000 claims 1
- TZBQHKVYDSXDFF-UHFFFAOYSA-N 2-[4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethoxyphenyl]acetic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C=C1)CC(=O)O)OCC)F TZBQHKVYDSXDFF-UHFFFAOYSA-N 0.000 claims 1
- AOONYWBXRCJZBL-UHFFFAOYSA-N 2-[5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-(difluoromethoxy)thiophen-2-yl]acetic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)CC(=O)O)OC(F)F)F AOONYWBXRCJZBL-UHFFFAOYSA-N 0.000 claims 1
- LFGFVQLYJJQWIM-UHFFFAOYSA-N 2-[5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]acetic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)CC(=O)O)OCC)F LFGFVQLYJJQWIM-UHFFFAOYSA-N 0.000 claims 1
- POOYSDGCTPSSCB-UHFFFAOYSA-N 2-[5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethylthiophen-2-yl]acetic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)CC(=O)O)CC)F POOYSDGCTPSSCB-UHFFFAOYSA-N 0.000 claims 1
- ZWMXGOGMAHSYRL-UHFFFAOYSA-N 2-[5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-propylthiophen-2-yl]acetic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)CC(=O)O)CCC)F ZWMXGOGMAHSYRL-UHFFFAOYSA-N 0.000 claims 1
- KGPPXZXCVUCFRH-UHFFFAOYSA-N 2-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-4-ethoxy-1,3-thiazole-5-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C=1SC(=C(N=1)OCC)C(=O)O)F KGPPXZXCVUCFRH-UHFFFAOYSA-N 0.000 claims 1
- BHKVCAWNQKTRTO-UHFFFAOYSA-N 2-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-4-ethyl-1,3-thiazole-5-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C=1SC(=C(N=1)CC)C(=O)O)F BHKVCAWNQKTRTO-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- TWCNGWQGTHPZFV-UHFFFAOYSA-N 2-cyclobutyloxy-4-[6-[2-(2-methoxy-4,5-dimethylphenyl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound C1(CCC1)OC1=C(C(=O)O)C=CC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C(=C1)C)C)OC TWCNGWQGTHPZFV-UHFFFAOYSA-N 0.000 claims 1
- YZMQSSRDJFHVIQ-UHFFFAOYSA-N 2-cyclobutyloxy-4-[6-[2-[4-(difluoromethyl)-5-fluoro-2-methoxyphenyl]ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound C1(CCC1)OC1=C(C(=O)O)C=CC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C(=C1)F)C(F)F)OC YZMQSSRDJFHVIQ-UHFFFAOYSA-N 0.000 claims 1
- JJIDHZWJDQKVTE-UHFFFAOYSA-N 2-ethoxy-4-[6-[2-(2-methoxy-4,5-dimethylphenyl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound C(C)OC1=C(C(=O)O)C=CC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C(=C1)C)C)OC JJIDHZWJDQKVTE-UHFFFAOYSA-N 0.000 claims 1
- DLHNDNVYCFGEKN-UHFFFAOYSA-N 2-ethoxy-4-[6-[2-[2-ethoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound C(C)OC1=C(C(=O)O)C=CC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)C(F)(F)F)OCC DLHNDNVYCFGEKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical compound O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 claims 1
- ZITZCKGXUGXQFD-UHFFFAOYSA-N 3-[4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethoxyphenoxy]propanoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(OCCC(=O)O)C=C1)OCC)F ZITZCKGXUGXQFD-UHFFFAOYSA-N 0.000 claims 1
- FJWLUPNOVVHNEP-UHFFFAOYSA-N 3-[4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethoxyphenyl]-4H-1,2,4-oxadiazol-5-one Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C=C1)C1=NOC(N1)=O)OCC)F FJWLUPNOVVHNEP-UHFFFAOYSA-N 0.000 claims 1
- UOANBDNPVAFJJK-UHFFFAOYSA-N 3-[5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophen-2-yl]propanoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)CCC(=O)O)OCC)F UOANBDNPVAFJJK-UHFFFAOYSA-N 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- CFNWAWZQCOZGLF-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(2-methoxy-4,5-dimethylphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C(=C1)C)C)OC)C(=O)O CFNWAWZQCOZGLF-UHFFFAOYSA-N 0.000 claims 1
- WXMAOHRSZYBKGQ-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(2-methoxy-4,6-dimethylphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1C)C)OC)C(=O)O WXMAOHRSZYBKGQ-UHFFFAOYSA-N 0.000 claims 1
- CMIVOKZCXIMEOV-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(2-methoxy-4-methylsulfanylphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)SC)OC)C(=O)O CMIVOKZCXIMEOV-UHFFFAOYSA-N 0.000 claims 1
- RAKHENFMCGDIJN-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(2-methoxy-6-methylphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=CC=C1C)OC)C(=O)O RAKHENFMCGDIJN-UHFFFAOYSA-N 0.000 claims 1
- VWPJAQUSHSTXCS-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(2-methylphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=CC=C1)C)C(=O)O VWPJAQUSHSTXCS-UHFFFAOYSA-N 0.000 claims 1
- KJJMIXJCWPWZEH-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(3-methoxycarbonylphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC(=CC=C1)C(=O)OC)C(=O)O KJJMIXJCWPWZEH-UHFFFAOYSA-N 0.000 claims 1
- YFUUNMPJQOEHTH-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(3-methoxyphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC(=CC=C1)OC)C(=O)O YFUUNMPJQOEHTH-UHFFFAOYSA-N 0.000 claims 1
- QJHINWAWLMLRRK-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-(4-methoxyphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC=C(C=C1)OC)C(=O)O QJHINWAWLMLRRK-UHFFFAOYSA-N 0.000 claims 1
- GTKRPVSVIQHDAI-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-[2-ethoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)C(F)(F)F)OCC)C(=O)O GTKRPVSVIQHDAI-UHFFFAOYSA-N 0.000 claims 1
- KSAUOKKPBBAIAO-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-[2-fluoro-6-methoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1OC)C(F)(F)F)F)C(=O)O KSAUOKKPBBAIAO-UHFFFAOYSA-N 0.000 claims 1
- JSHINVDTYNQWJV-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-[2-methoxy-4-(trifluoromethoxy)phenyl]ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)OC(F)(F)F)OC)C(=O)O JSHINVDTYNQWJV-UHFFFAOYSA-N 0.000 claims 1
- NFDAGUJTUVXZOL-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-[2-methoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=C(C=C(C=C1)C(F)(F)F)OC)C(=O)O NFDAGUJTUVXZOL-UHFFFAOYSA-N 0.000 claims 1
- QKTAIZOOEIUNRG-UHFFFAOYSA-N 3-ethoxy-5-[6-[2-[4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound C(C)OC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC=C(C=C1)C(F)(F)F)C(=O)O QKTAIZOOEIUNRG-UHFFFAOYSA-N 0.000 claims 1
- NJHSRNGDZGANPF-UHFFFAOYSA-N 3-fluoro-5-[6-[2-(4-methylphenyl)ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound FC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC=C(C=C1)C)C(=O)O NJHSRNGDZGANPF-UHFFFAOYSA-N 0.000 claims 1
- SGOSKDJSVLUJDZ-UHFFFAOYSA-N 3-fluoro-5-[6-[2-[4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]thiophene-2-carboxylic acid Chemical compound FC1=C(SC(=C1)C1=NC=NC(=C1)NCCC1=CC=C(C=C1)C(F)(F)F)C(=O)O SGOSKDJSVLUJDZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- FHBLJHRVHHAUMX-UHFFFAOYSA-N 4-[6-[2-(2,6-difluoro-4-methoxyphenyl)ethylamino]pyrimidin-4-yl]-2-methylsulfanylbenzoic acid Chemical compound FC1=C(C(=CC(=C1)OC)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SC FHBLJHRVHHAUMX-UHFFFAOYSA-N 0.000 claims 1
- INWMQYJLDUVXRH-UHFFFAOYSA-N 4-[6-[2-(2-methoxy-4,5-dimethylphenyl)ethylamino]pyrimidin-4-yl]-2-methylsulfanylbenzoic acid Chemical compound COC1=C(C=C(C(=C1)C)C)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SC INWMQYJLDUVXRH-UHFFFAOYSA-N 0.000 claims 1
- MQUORJSBJQMRPJ-UHFFFAOYSA-N 4-[6-[2-(2-methoxy-4-methylsulfanylphenyl)ethylamino]pyrimidin-4-yl]-2-methylsulfanylbenzoic acid Chemical compound COC1=C(C=CC(=C1)SC)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SC MQUORJSBJQMRPJ-UHFFFAOYSA-N 0.000 claims 1
- YVWPXDRGEPYNCG-UHFFFAOYSA-N 4-[6-[2-(3,4-dimethylphenyl)ethylamino]pyrimidin-4-yl]-2-methylsulfanylbenzoic acid Chemical compound CC=1C=C(C=CC=1C)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SC YVWPXDRGEPYNCG-UHFFFAOYSA-N 0.000 claims 1
- IAWFSZPIVVFXSY-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-(2-hydroxyethoxy)benzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OCCO)F IAWFSZPIVVFXSY-UHFFFAOYSA-N 0.000 claims 1
- XRTMZLUVZPGQIB-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-(2-methylpropoxy)benzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OCC(C)C)F XRTMZLUVZPGQIB-UHFFFAOYSA-N 0.000 claims 1
- HTCBIGIGZXHIRT-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-(2-methylpropyl)benzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)CC(C)C)F HTCBIGIGZXHIRT-UHFFFAOYSA-N 0.000 claims 1
- KHLXRYKEUGYJQN-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-(difluoromethoxy)benzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OC(F)F)F KHLXRYKEUGYJQN-UHFFFAOYSA-N 0.000 claims 1
- JLCFCZYWCOFPLT-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-butoxy-6-fluorobenzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C(=C1)F)OCCCC)F JLCFCZYWCOFPLT-UHFFFAOYSA-N 0.000 claims 1
- NOZWHSHETZKCIO-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-butoxybenzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OCCCC)F NOZWHSHETZKCIO-UHFFFAOYSA-N 0.000 claims 1
- PXCFUKZMPJMQFI-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-cyclobutyloxybenzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OC1CCC1)F PXCFUKZMPJMQFI-UHFFFAOYSA-N 0.000 claims 1
- PTSMCYQGOCZEKH-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethoxy-N-methylsulfonylbenzamide Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)NS(=O)(=O)C)C=C1)OCC)F PTSMCYQGOCZEKH-UHFFFAOYSA-N 0.000 claims 1
- DVMAUISIYBHXLQ-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethylsulfanylbenzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SCC)F DVMAUISIYBHXLQ-UHFFFAOYSA-N 0.000 claims 1
- GOKAGCLEIFMRKD-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-methylsulfanylbenzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SC)F GOKAGCLEIFMRKD-UHFFFAOYSA-N 0.000 claims 1
- WSUXZEIVWSMEKE-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-propoxybenzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OCCC)F WSUXZEIVWSMEKE-UHFFFAOYSA-N 0.000 claims 1
- FHKKQFHJNMTBLS-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-propylbenzoic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)CCC)F FHKKQFHJNMTBLS-UHFFFAOYSA-N 0.000 claims 1
- WONIPCVHNUILHG-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2-ethoxyphenyl)ethylamino]pyrimidin-4-yl]-2-ethoxybenzoic acid Chemical compound BrC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OCC)OCC WONIPCVHNUILHG-UHFFFAOYSA-N 0.000 claims 1
- CAHQYIXNQXEXPL-UHFFFAOYSA-N 4-[6-[2-(4-bromo-2-fluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethoxybenzoic acid Chemical compound BrC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)OCC)F CAHQYIXNQXEXPL-UHFFFAOYSA-N 0.000 claims 1
- VQNWBGFHRJDKLL-UHFFFAOYSA-N 4-[6-[2-[2-ethoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]-2-methylsulfanylbenzoic acid Chemical compound C(C)OC1=C(C=CC(=C1)C(F)(F)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SC VQNWBGFHRJDKLL-UHFFFAOYSA-N 0.000 claims 1
- CWRVMYFILBALNG-UHFFFAOYSA-N 4-[6-[2-[2-ethoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]-2-propylbenzoic acid Chemical compound C(C)OC1=C(C=CC(=C1)C(F)(F)F)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)CCC CWRVMYFILBALNG-UHFFFAOYSA-N 0.000 claims 1
- YSWRYAJYAVNSMN-UHFFFAOYSA-N 4-[6-[2-[4-(difluoromethoxy)-2-methoxyphenyl]ethylamino]pyrimidin-4-yl]-2-methylsulfanylbenzoic acid Chemical compound FC(OC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(C(=O)O)C=C1)SC)OC)F YSWRYAJYAVNSMN-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- ZMUBAEDFKODQDU-UHFFFAOYSA-N 5-[4-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-2-ethoxyphenyl]-1,2-oxazol-3-one Chemical compound BrC1=CC(=C(CCNC2=CC(=NC=N2)C2=CC(=C(C=C2)C2=CC(NO2)=O)OCC)C(=C1)F)F ZMUBAEDFKODQDU-UHFFFAOYSA-N 0.000 claims 1
- CNHWYDVPKOPHGW-UHFFFAOYSA-N 5-[6-[2-(2,4-dichlorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)Cl)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC CNHWYDVPKOPHGW-UHFFFAOYSA-N 0.000 claims 1
- GYRLNPJDNNDWJO-UHFFFAOYSA-N 5-[6-[2-(2,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound COC1=C(C=CC(=C1)OC)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC GYRLNPJDNNDWJO-UHFFFAOYSA-N 0.000 claims 1
- AOFWJNZVNGKMRB-UHFFFAOYSA-N 5-[6-[2-(2,4-dimethylphenyl)ethylamino]pyrimidin-4-yl]-3-(trifluoromethyl)thiophene-2-carboxylic acid Chemical compound CC1=C(C=CC(=C1)C)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)C(F)(F)F AOFWJNZVNGKMRB-UHFFFAOYSA-N 0.000 claims 1
- JFPFJIXOGLXHKY-UHFFFAOYSA-N 5-[6-[2-(2,5-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound COC1=C(C=C(C=C1)OC)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC JFPFJIXOGLXHKY-UHFFFAOYSA-N 0.000 claims 1
- KRNOHFBNBDOFLD-UHFFFAOYSA-N 5-[6-[2-(2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethylthiophene-2-carboxylic acid Chemical compound FC1=C(C(=CC=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)CC KRNOHFBNBDOFLD-UHFFFAOYSA-N 0.000 claims 1
- IOCNFVMVCQBVSQ-UHFFFAOYSA-N 5-[6-[2-(3,4-dichloro-2-methylphenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound ClC=1C(=C(C=CC=1Cl)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC)C IOCNFVMVCQBVSQ-UHFFFAOYSA-N 0.000 claims 1
- YRSGHOPGASKUSK-UHFFFAOYSA-N 5-[6-[2-(3,4-dimethylphenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound CC=1C=C(C=CC=1C)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC YRSGHOPGASKUSK-UHFFFAOYSA-N 0.000 claims 1
- OVMKFCFBWDWWTR-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-(2-hydroxyethoxy)thiophene-2-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCCO)F OVMKFCFBWDWWTR-UHFFFAOYSA-N 0.000 claims 1
- DGFWNXOSDWVHHI-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-chlorothiophene-2-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)Cl)F DGFWNXOSDWVHHI-UHFFFAOYSA-N 0.000 claims 1
- FKIKUKVKUWYWIK-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxy-N-methylsulfonylthiophene-2-carboxamide Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)NS(=O)(=O)C)OCC)F FKIKUKVKUWYWIK-UHFFFAOYSA-N 0.000 claims 1
- NSRAWTJNQLKZJJ-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxy-N-sulfamoylthiophene-2-carboxamide Chemical compound BrC1=CC(=C(CCNC2=CC(=NC=N2)C2=CC(=C(S2)C(=O)NS(N)(=O)=O)OCC)C(=C1)F)F NSRAWTJNQLKZJJ-UHFFFAOYSA-N 0.000 claims 1
- KEWXAZISKAYEJV-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-ethylthiophene-2-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)CC)F KEWXAZISKAYEJV-UHFFFAOYSA-N 0.000 claims 1
- ZJFNKSJDAXELCF-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-methoxythiophene-2-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OC)F ZJFNKSJDAXELCF-UHFFFAOYSA-N 0.000 claims 1
- DYLLFFFNYNZFEZ-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-3-methylthiophene-2-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)C)F DYLLFFFNYNZFEZ-UHFFFAOYSA-N 0.000 claims 1
- VOSSLMOQQFOLIK-UHFFFAOYSA-N 5-[6-[2-(4-bromo-2,6-difluorophenyl)ethylamino]pyrimidin-4-yl]-4-chloro-3-ethoxythiophene-2-carboxylic acid Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=CC(=NC=N1)C1=C(C(=C(S1)C(=O)O)OCC)Cl)F VOSSLMOQQFOLIK-UHFFFAOYSA-N 0.000 claims 1
- XJDBUCFXLIGFSN-UHFFFAOYSA-N 5-[6-[2-(4-bromophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound BrC1=CC=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC XJDBUCFXLIGFSN-UHFFFAOYSA-N 0.000 claims 1
- XPUUZZNEHUPCFL-UHFFFAOYSA-N 5-[6-[2-(4-chloro-2-nitrophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound ClC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC)[N+](=O)[O-] XPUUZZNEHUPCFL-UHFFFAOYSA-N 0.000 claims 1
- IBBWJRHSVGJWSX-UHFFFAOYSA-N 5-[6-[2-(4-chlorophenyl)ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound ClC1=CC=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC IBBWJRHSVGJWSX-UHFFFAOYSA-N 0.000 claims 1
- LPFYUIPLZGZGIH-UHFFFAOYSA-N 5-[6-[2-(4-methylphenyl)ethylamino]pyrimidin-4-yl]-3-(trifluoromethyl)thiophene-2-carboxylic acid Chemical compound C1(=CC=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)C(F)(F)F)C LPFYUIPLZGZGIH-UHFFFAOYSA-N 0.000 claims 1
- FXTLBXLVVVSAJA-UHFFFAOYSA-N 5-[6-[2-[2-(difluoromethoxy)-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound FC(OC1=C(C=CC(=C1)C(F)(F)F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC)F FXTLBXLVVVSAJA-UHFFFAOYSA-N 0.000 claims 1
- NPUWSYZOZDHYCH-UHFFFAOYSA-N 5-[6-[2-[4-(difluoromethoxy)-2-methoxyphenyl]ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound FC(OC1=CC(=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC)OC)F NPUWSYZOZDHYCH-UHFFFAOYSA-N 0.000 claims 1
- NCVJZIZJGHUHLY-UHFFFAOYSA-N 5-[6-[2-[4-(difluoromethyl)-5-fluoro-2-methoxyphenyl]ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound FC(C1=CC(=C(C=C1F)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC)OC)F NCVJZIZJGHUHLY-UHFFFAOYSA-N 0.000 claims 1
- XVHOCSWPBKLVST-UHFFFAOYSA-N 5-[6-[2-[5-chloro-2-methoxy-4-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]-3-ethoxythiophene-2-carboxylic acid Chemical compound ClC=1C(=CC(=C(C=1)CCNC1=CC(=NC=N1)C1=CC(=C(S1)C(=O)O)OCC)OC)C(F)(F)F XVHOCSWPBKLVST-UHFFFAOYSA-N 0.000 claims 1
- YLSUGACLIOXGSH-UHFFFAOYSA-N BrC1=CC=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(C=C1)C1=NOC(N1)=O)OCC Chemical compound BrC1=CC=C(C=C1)CCNC1=CC(=NC=N1)C1=CC(=C(C=C1)C1=NOC(N1)=O)OCC YLSUGACLIOXGSH-UHFFFAOYSA-N 0.000 claims 1
- PBFGJYQMRPZKEH-UHFFFAOYSA-N Cc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 Chemical compound Cc1cc(sc1-c1nc(=O)o[nH]1)-c1cc(NCCc2c(F)cc(Br)cc2F)ncn1 PBFGJYQMRPZKEH-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- IJQZGVXLGNKJTK-UHFFFAOYSA-N N-[2-(4-bromo-2,6-difluorophenyl)ethyl]-6-[3-ethoxy-4-(2H-tetrazol-5-yl)phenyl]pyrimidin-4-amine Chemical compound BrC1=CC(=C(C(=C1)F)CCNC1=NC=NC(=C1)C1=CC(=C(C=C1)C1=NN=NN1)OCC)F IJQZGVXLGNKJTK-UHFFFAOYSA-N 0.000 claims 1
- PCVJZQPCMCEXBI-UHFFFAOYSA-N N-[2-(4-bromophenyl)ethyl]-6-[4-ethoxy-5-(2H-tetrazol-5-yl)thiophen-2-yl]pyrimidin-4-amine Chemical compound BrC1=CC=C(C=C1)CCNC1=NC=NC(=C1)C=1SC(=C(C=1)OCC)C1=NN=NN1 PCVJZQPCMCEXBI-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 150000002926 oxygen Chemical group 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017062031 | 2017-05-18 | ||
| EPPCT/EP2017/062031 | 2017-05-18 | ||
| PCT/EP2018/062862 WO2018210994A1 (en) | 2017-05-18 | 2018-05-17 | Phenyl derivatives as pge2 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520356A JP2020520356A (ja) | 2020-07-09 |
| JP2020520356A5 true JP2020520356A5 (enExample) | 2021-07-26 |
| JP7159214B2 JP7159214B2 (ja) | 2022-10-24 |
Family
ID=62186480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563491A Active JP7159214B2 (ja) | 2017-05-18 | 2018-05-17 | Ｐｇｅ２レセプター調節剤としてのフェニル誘導体 |
Country Status (32)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| WO2019183245A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3906028A4 (en) * | 2018-12-31 | 2022-10-12 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
| WO2022102731A1 (ja) | 2020-11-13 | 2022-05-19 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
| WO2022272062A1 (en) | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AU2000234451B2 (en) | 2000-03-24 | 2005-09-29 | Asterand Uk Acquisition Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| WO2003086390A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Japan Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
| CA2482382A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| WO2003099857A1 (en) | 2002-05-23 | 2003-12-04 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| PT1603893E (pt) | 2003-01-29 | 2008-08-21 | Asterand Uk Ltd | Antagonistas dos receptores ep4 |
| TW200509938A (en) | 2003-08-26 | 2005-03-16 | Teijin Pharma Ltd | Pyrrolopyrimidine thion derivatives |
| CA2536870C (en) | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EP1756043B1 (en) | 2004-05-04 | 2009-07-01 | RaQualia Pharma Inc | Ortho substituted aryl or heteroaryl amide compounds |
| CN1950333A (zh) | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| JP5289046B2 (ja) | 2005-05-19 | 2013-09-11 | メルク カナダ インコーポレイテッド | Ｅｐ４アンタゴニストとしてのキノリン誘導体 |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
| WO2007121578A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| AU2007260529B2 (en) | 2006-06-12 | 2012-04-19 | Merck Canada Inc. | Indoline amide derivatives as EP4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| AR061974A1 (es) | 2006-07-14 | 2008-08-10 | Novartis Ag | Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion |
| ES2421453T3 (es) | 2006-08-11 | 2013-09-02 | Merck Frosst Canada Ltd | Derivados de tiofenocarboxamida como ligandos del receptor EP4 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| WO2008116304A1 (en) | 2007-03-26 | 2008-10-02 | Merck Frosst Canada Ltd. | Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists |
| JPWO2008123207A1 (ja) | 2007-03-26 | 2010-07-15 | アステラス製薬株式会社 | オルニチン誘導体 |
| EP2014657A1 (de) | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| EP2460787A1 (en) | 2007-07-03 | 2012-06-06 | Astellas Pharma Inc. | Amide compounds and their use as PGE2 antagonists. |
| NZ584454A (en) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases |
| CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| RU2479576C9 (ru) | 2008-05-14 | 2014-03-10 | Астеллас Фарма Инк. | Амидное соединение |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| EP2320906B1 (en) | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| CN102164942B (zh) | 2008-09-19 | 2017-02-15 | 生物科技研究有限公司 | 三萜系化合物及其使用的方法 |
| MX2011003166A (es) | 2008-09-25 | 2011-04-27 | Merck Frosst Canada Ltd | Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4. |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| WO2011063181A1 (en) | 2009-11-23 | 2011-05-26 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
| WO2011144742A1 (en) | 2010-05-21 | 2011-11-24 | Chemilia Ab | Novel pyrimidine derivatives |
| SMT201700008T1 (it) | 2010-09-21 | 2017-03-08 | Eisai R&D Man Co Ltd | Composizione farmaceutica |
| US9175080B2 (en) | 2010-09-29 | 2015-11-03 | Nb Health Laboratory Co., Ltd. | Antibody against human prostaglandin E2 receptor EP4 |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| EP2640702A1 (en) | 2010-11-17 | 2013-09-25 | Novartis AG | 3-(aminoaryl)-pyridine compounds |
| ES2545110T3 (es) | 2010-12-10 | 2015-09-08 | Rottapharm Biotech S.R.L. | Derivados de piridinamida como antagonistas del receptor EP4 |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
| WO2012149528A1 (en) | 2011-04-29 | 2012-11-01 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| US9518044B2 (en) | 2011-06-20 | 2016-12-13 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| DK2729445T3 (en) | 2011-07-04 | 2016-01-18 | Rottapharm Biotech Srl | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| BR112015011497B1 (pt) | 2012-11-27 | 2023-01-10 | Thomas Helledays Stiftelse För Medicinsk Forskning | Composto, e, formulação farmacêutica |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| SI3004082T1 (sl) | 2013-05-30 | 2017-11-30 | Idorsia Pharmaceuticals Ltd | Modulatorji receptorja CXCR7 |
| HUE039015T2 (hu) | 2013-06-12 | 2018-12-28 | Kaken Pharma Co Ltd | 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény |
| EA029901B1 (ru) | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
| DK3363790T3 (da) | 2013-09-06 | 2020-04-27 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazolderivater som immunmodulatorer |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| RS57306B1 (sr) | 2013-10-17 | 2018-08-31 | Vertex Pharma | Inhibitori dnk-pk |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| PL3083562T3 (pl) | 2013-12-17 | 2018-02-28 | Eli Lilly & Company | Pochodne fenoksyetylowych cyklicznych amin i ich aktywność jako modulatorów receptora EP4 |
| WO2015094912A1 (en) | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Dimethylbenzoic acid compounds |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| WO2015167825A1 (en) | 2014-04-29 | 2015-11-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| CN110354266A (zh) | 2014-05-23 | 2019-10-22 | 卫材 R&D 管理有限公司 | 用于治疗癌症的组合疗法 |
| SG11201609981RA (en) | 2014-06-04 | 2016-12-29 | Thomas Helledays Stiftelse För Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
| EP3157916B1 (en) | 2014-06-19 | 2018-12-12 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| KR102559499B1 (ko) | 2015-01-09 | 2023-07-25 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 스피로 화합물 |
| WO2017014323A1 (en) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| CA3002144C (en) | 2015-10-16 | 2024-01-23 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CA3030783A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
-
2018
- 2018-05-17 WO PCT/EP2018/062862 patent/WO2018210994A1/en not_active Ceased
- 2018-05-17 CA CA3060597A patent/CA3060597A1/en active Pending
- 2018-05-17 BR BR112019024109-4A patent/BR112019024109A2/pt not_active IP Right Cessation
- 2018-05-17 AR ARP180101315A patent/AR111941A1/es not_active Application Discontinuation
- 2018-05-17 SI SI201830422T patent/SI3625222T1/sl unknown
- 2018-05-17 JP JP2019563491A patent/JP7159214B2/ja active Active
- 2018-05-17 PT PT18725222T patent/PT3625222T/pt unknown
- 2018-05-17 MX MX2019013718A patent/MX388256B/es unknown
- 2018-05-17 MA MA49126A patent/MA49126B1/fr unknown
- 2018-05-17 EA EA201992676A patent/EA201992676A1/ru unknown
- 2018-05-17 HU HUE18725222A patent/HUE056080T2/hu unknown
- 2018-05-17 PL PL18725222T patent/PL3625222T3/pl unknown
- 2018-05-17 CN CN201880031321.4A patent/CN110612296A/zh active Pending
- 2018-05-17 US US16/614,594 patent/US11712438B2/en active Active
- 2018-05-17 ES ES18725222T patent/ES2893452T3/es active Active
- 2018-05-17 SG SG11201908729U patent/SG11201908729UA/en unknown
- 2018-05-17 TW TW107116759A patent/TWI765041B/zh not_active IP Right Cessation
- 2018-05-17 AU AU2018269666A patent/AU2018269666B2/en not_active Ceased
- 2018-05-17 KR KR1020197037298A patent/KR102632028B1/ko active Active
- 2018-05-17 CR CR20190559A patent/CR20190559A/es unknown
- 2018-05-17 UA UAA201911975A patent/UA125123C2/uk unknown
- 2018-05-17 EP EP18725222.6A patent/EP3625222B1/en active Active
- 2018-05-17 PE PE2019002396A patent/PE20191814A1/es unknown
- 2018-05-17 HR HRP20211533TT patent/HRP20211533T1/hr unknown
- 2018-05-17 RS RS20211256A patent/RS62440B1/sr unknown
- 2018-05-17 IL IL270623A patent/IL270623B2/en unknown
- 2018-05-17 LT LTEPPCT/EP2018/062862T patent/LT3625222T/lt unknown
- 2018-05-17 DK DK18725222.6T patent/DK3625222T3/da active
-
2019
- 2019-09-27 CO CONC2019/0010578A patent/CO2019010578A2/es unknown
- 2019-11-15 CL CL2019003275A patent/CL2019003275A1/es unknown
- 2019-11-15 PH PH12019502563A patent/PH12019502563A1/en unknown
-
2021
- 2021-10-19 CY CY20211100906T patent/CY1124608T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520356A5 (enExample) | ||
| JP2020520357A5 (enExample) | ||
| HRP20211533T1 (hr) | Derivati fenila kao modulatori receptora pge2 | |
| JP2020520354A5 (enExample) | ||
| RU2019118623A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
| JP2020502103A5 (enExample) | ||
| JP6464139B2 (ja) | ブロモドメイン含有タンパク質の阻害のための方法および組成物 | |
| RU2573834C2 (ru) | ФАРМАЦЕВТИЧЕСКИ АКТИВНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl | |
| JP2009524589A5 (ja) | 置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用 | |
| RU2019120990A (ru) | Бициклические гетероарильные производные в качестве стимуляторов cftr | |
| JP2020519589A5 (enExample) | ||
| JP2008523041A5 (enExample) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2020520358A5 (enExample) | ||
| JP2011503166A5 (enExample) | ||
| JP2018534328A5 (enExample) | ||
| JP2017512794A5 (enExample) | ||
| HRP20131105T1 (hr) | Derivati aminopirazola | |
| JP2010533158A5 (enExample) | ||
| JP2020516671A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| IL259424A (en) | History of indole converted to nitrogen as pge2 receptor modulators | |
| JP2008513514A5 (enExample) | ||
| JP2004511469A5 (enExample) | ||
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы |